Skip to main content
. 2022 Apr 20;10(4):e004218. doi: 10.1136/jitc-2021-004218

Figure 5.

Figure 5

BEMPEG+NKTR-262 treatment induces CD8+ T cells in the tumor with reduced checkpoint receptor expression and increased functional marker expression than BEMPEG+RT. (A) Representative flow cytometry gating strategy for CT26 tumors harvested 7 days post-therapy. (B) Percent (left) and density (right) of CD8+ T cells in the tumor. N=8–18, from three or four independent experiments. (C) Checkpoint receptors expressed on CD8+ T cells in the tumor. N=15 for PD-1 (from three experiments), 5 for Tim-3 and LAG-3 (from one experiment). (D) Activation markers expressed on CD8+ T cells in the tumor. For ICOS, N=5–9 from two experiments; for GzmA, N=13–23 from four experiments; for Ki-67, N=9–13 from three experiments. (E) Frequency of AH1-A5+ CD8+ T cells. N=15–20 from four experiments. For comparisons among treatment groups, one-way ANOVA with Šídáks multiple comparisons test. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001. NT, non-treated tumor; RT, radiation therapy; T, treated tumor.